Deep Dive: Regulatory Status of Popular Compounded Peptides Holt Law FDA considers adding a dozen peptides to its bulk drug compounding list RAPS FDA Peptide Reclassification 2026: What It Means for Providers The FDA may be about to change everything for peptide research. Secretary RFK Jr. announced plans to move 14 peptides from Category 2 to Category 1. That means FDA recognized. Potentially prescribable through FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog The Blacklisting of Peptides